EUVIMEDEUVIMED entdecken
Crossref

Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss

Yagiz Matthew Akiska, Paradi Mirmirani, Ingrid Roseborough, Erin Mathes, Tina Bhutani, Andrew Ambrosy, Crystal Aguh, Wilma Bergfeld, Valerie D Callender, Leslie Castelo-Soccio, George Cotsarelis, Brittany Gareth Craiglow und 35 weitere

JAMA Dermatology · 01.01.2025 · 161 (1) · 87

DOI: 10.1001/jamadermatol.2024.4593 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Dermatology, erschienen am 01.01.2025. Verfasst von Yagiz Matthew Akiska und 46 weiteren Autor:innen. Beteiligte Einrichtung: George Washington University School of Medicine & Health Sciences, Washington, DC. Hauptthemen laut MEDLINE: Minoxidil, Alopecia, Vasodilator Agents. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The results of small studies suggest that off-label use of low-dose oral minoxidil (LDOM) may be safe and effective for patients with hair loss, but larger trials and standardized guidelines are lacking.

Objective

To create an expert consensus statement for LDOM prescribing for patients with hair loss. Evidence Review The current literature on the pharmacological properties, adverse effect profile, and use of LDOM for patients with hair loss was reviewed. Topics of interest were identified, and a modified Delphi consensus process was created. A total of 43 hair loss specialist dermatologists from 12 countries participated in a modified Delphi process. Consensus was reached if at least 70% agreed or strongly agreed on a 5-point Likert scale.

Findings

Over 4 survey rounds, 180 items in the first round, 121 items in the second round, 16 items in the third round, and 11 items in the fourth round were considered and revised. A total of 76 items achieved consensus including diagnoses for which LDOM may provide direct or supportive benefit, indications for LDOM compared to topical minoxidil, dosing for adults (18 years and older) and adolescents (aged 12 to 17 years), contraindications, precautions, baseline evaluation, monitoring, adjunctive therapy, and specialty consultation. Pediatric use and dosing items for children younger than 12 years, and LDOM titration protocols fell short of consensus. Conclusions and Relevance This international expert consensus statement regarding the off-label prescribing of LDOM for patients with hair loss can help guide clinical practice until more data emerge. Hair loss experts with experience treating pediatric patients were underrepresented on this expert panel. Future research should investigate best practices for LDOM use in pediatric patients. Other critical topics for further investigation include the comparative efficacy of topical minoxidil vs oral minoxidil, the safety of oral minoxidil for patients with a history of allergic contact dermatitis to topical minoxidil, the long-term safety of LDOM, and the use of other off-label forms of minoxidil, such as compounded formulations of oral minoxidil and sublingual minoxidil. As additional evidence-based data emerge, these recommendations should be updated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MinoxidilAlopeciaVasodilator AgentsHumansDelphi TechniqueAdministration, OralOff-Label UseChildAdolescentAdult

Substanzen

MinoxidilVasodilator Agents

Autor:innen und Institutionen

  • George Washington University School of Medicine & Health Sciences, Washington, DC.
  • Department of Dermatology, The Permanente Medical Group, Vallejo, California.
  • Department of Dermatology, University of California, San Francisco.
  • Division of Research, Kaiser Permanente Northern California, San Francisco.
  • Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, California.
  • Johns Hopkins School of Medicine, Baltimore, Maryland.

Zitieren

APA

Akiska, Y. M., Mirmirani, P., Roseborough, I., Mathes, E., Bhutani, T., Ambrosy, A., Aguh, C., Bergfeld, W., Callender, V. D., Castelo-Soccio, L., Cotsarelis, G., Craiglow, B. G., Desai, N. S., Doche, I., Duque-Estrada, B., Elston, D. M., Goh, C., Goldberg, L. J., Grimalt, R., …, & Fu, J. M. (2025). Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss. JAMA Dermatology, 161(1), 87. https://doi.org/10.1001/jamadermatol.2024.4593

Vancouver

Akiska YM, Mirmirani P, Roseborough I, Mathes E, Bhutani T, Ambrosy A, et al. Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss. JAMA Dermatology. 2025;161(1):87. doi:10.1001/jamadermatol.2024.4593

BibTeX
@article{Akiska2025,
  author = {Akiska, Yagiz Matthew and Mirmirani, Paradi and Roseborough, Ingrid and Mathes, Erin and Bhutani, Tina and Ambrosy, Andrew and Aguh, Crystal and Bergfeld, Wilma and Callender, Valerie D and Castelo-Soccio, Leslie and Cotsarelis, George and Craiglow, Brittany Gareth and Desai, Nisha S and Doche, Isabella and Duque-Estrada, Bruna and Elston, Dirk M and Goh, Carolyn and Goldberg, Lynne J and Grimalt, Ramon and Jabbari, Ali and Jolliffe, Victoria and King, Brett A and LaSenna, Charlotte and Lenzy, Yolanda and Lester, Jenna C and Lortkipanidze, Nino and Lo Sicco, Kristen I and McMichael, Amy and Meah, Nekma and Mesinkovska, Natasha and Miteva, Mariya and Mostaghimi, Arash and Ovcharenko, Yuliya and Piliang, Melissa and Piraccini, Bianca Maria and Rakowska, Adriana and Salkey, Kimberly S and Schmidt, Adriana and Shapiro, Jerry and Sibbald, Cathryn and Sinclair, Rodney and Suchonwanit, Poonkiat and Taylor, Susan and Tosti, Antonella and Vañó-Galván, Sergio and Wall, Dmitri Robert and Fu, Jennifer M},
  title = {Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss},
  journal = {JAMA Dermatology},
  year = {2025},
  volume = {161},
  number = {1},
  pages = {87},
  doi = {10.1001/jamadermatol.2024.4593}
}
Kostenlos starten →